MOTS-c is a mitochondria-derived peptide that people research for metabolism and exercise-related cellular energy, and telos rx now offers it after provider review. When this article first went up, it was not available here. This article answers the questions people ask most, plainly and without hype.
MOTS-c was previously not part of the telos rx program. It is now offered as a compounded subcutaneous injection after an online intake reviewed by a US-licensed provider, who sets the dose and schedule. A prescription is required and approval is not guaranteed. See the MOTS-c page for how it works. telos rx also offers BPC-157, PT-141, NAD+ nasal spray, and sermorelin.
What is MOTS-c
MOTS-c is a short peptide, sixteen amino acids long. It is unusual because it is encoded inside the mitochondrial genome, rather than the main nuclear genome that most proteins come from. Researchers grouped it into a class called mitochondrial-derived peptides after it was first described in the scientific literature roughly a decade ago.
The interest in MOTS-c comes from its proposed role as a signal that travels from mitochondria, the structures inside cells that generate usable energy, back to the rest of the cell. That kind of two-way communication between mitochondria and the nucleus is a genuinely active area of metabolic research. It is part of why the peptide keeps coming up in conversations about fitness and aging, even outside academic circles.
telos rx previously did not offer MOTS-c. It now prescribes compounded MOTS-c after provider review, under the conditions of a temporary HHS policy described below. That is a program decision, and it is not a claim that the science is settled. You can read more on the MOTS-c page.
Patients who ask about MOTS-c are usually not asking out of nowhere. They have read a forum thread, watched a video, or seen it mentioned alongside other peptides they already know, and they want a straight answer about where things stand. This article is that answer.
Is MOTS-c legal to buy
This is one of the most common questions, and the honest answer is that it depends heavily on how it is sold. MOTS-c shows up widely in the research chemical market. It is typically labeled "not for human consumption," which is a real regulatory category with real limits. That label is not a loophole that makes personal use safe or sanctioned.
Buying a substance labeled for research use and then using it yourself sits in a legal and safety gray area that telos rx will not operate in. That is why telos rx offers MOTS-c only as a prescription compounded by a state-licensed pharmacy.
The NIH's general guidance on evaluating unregulated health products, in using dietary supplements wisely, is a useful lens even though a research-labeled peptide is not technically a supplement. The underlying caution translates directly: unregulated does not mean tested, and available for purchase does not mean appropriate for you.
Purity and dosing accuracy are also open questions for products sold this way. Without pharmacy-level quality control, there is no reliable way to know what is actually in a given vial. That uncertainty is one more reason telos rx keeps its compounding program limited to what it can source and verify properly, batch by batch.
Key takeaway: "Available for research purposes" and "available as a compounded prescription" are two very different things. telos rx only offers the second kind. MOTS-c was not in that group before, and it is now, after provider review.
Why wasn't it compounded like BPC-157
People used to ask why telos rx compounded BPC-157 but not MOTS-c, since both circulate in similar online conversations. Until recently, telos rx had not added MOTS-c to its program. Here is what changed.
A 2026 review by the FDA's Pharmacy Compounding Advisory Committee made non-binding recommendations about several research peptides, MOTS-c among them. A recommendation from an advisory committee is a step in a process, not a regulatory approval. Separately, on October 28, 2026, HHS announced an interim enforcement discretion policy covering six peptides, MOTS-c among them: HHS does not intend to take enforcement action against state-licensed pharmacies that compound single-ingredient MOTS-c for subcutaneous or intramuscular injection with a valid prescription, under strict sourcing, testing and reporting conditions. That policy is temporary while FDA rulemaking continues, it is not FDA approval, and HHS can revisit it. telos rx did not add MOTS-c on the basis of the committee recommendation alone. It added MOTS-c once the HHS policy set out these conditions.
Compounded medications in general, including the ones telos rx does offer, are not FDA-approved. That is a separate point from whether a specific peptide has cleared the additional bar telos rx applies before adding anything new to its program. For background on how compounding is regulated, see the FDA overview of drug compounding.
What do people actually use it for
Most of the interest people describe centers on metabolism, insulin sensitivity, and how the body responds to exercise. MOTS-c circulating levels have been observed to change with physical activity in some published research, which is part of why it gets discussed alongside fitness and metabolic health.
Some people also ask about it in the context of general aging and longevity, since mitochondrial function tends to decline with age and MOTS-c sits inside that broader conversation. That framing is common online, but it runs well ahead of what has actually been established.
None of that describes an approved use, a standard dose, or an established safety profile in humans. It describes a research direction. Treating a research direction as a usable protocol is exactly the gap telos rx is trying not to paper over with marketing language.
How patients typically find their way here
Two groups tend to ask about MOTS-c. The first is people already using a telos rx protocol, like BPC-157, who see the peptide mentioned in the same online spaces and want to know if it is next. The second is people newer to peptide research entirely, comparing options before they commit to anything.
Both groups deserve the same answer. MOTS-c was previously not available through telos rx, for regulatory rather than arbitrary reasons. It is now offered after provider review, and NAD+ nasal spray remains a separate option if the goal is cellular energy or general metabolic support.
Does telos rx offer it now
Yes. Program decisions follow regulatory clarity and internal review, not demand alone, and the October 2026 HHS policy provided that clarity, at least for now. The MOTS-c page is where telos rx reflects current status, and it will change if HHS revisits the policy.
If cellular energy, metabolism, or general wellness is what drew you to MOTS-c, it comes with an actual clinical intake rather than an unregulated purchase. A US-licensed provider reviews your answers and, if MOTS-c fits, sets the dose and schedule. NAD+ nasal spray is a separate compounded protocol built around a related idea. If you want to start, you can begin a MOTS-c intake today.
How to think about the research honestly
It helps to separate three different things that often get blended together in online discussion: laboratory findings, animal studies, and confirmed human outcomes. MOTS-c research includes work at all three levels, but the amount of confirmed human data is still limited compared to a peptide with an established clinical history.
That is not unusual for a peptide this early in its research life. It does mean that any specific claim about what MOTS-c does in a person should be treated with real skepticism. That is especially true for claims based only on cell culture or animal studies, until better human evidence exists.
If you want to look at the primary literature yourself, rather than relying on secondhand summaries, searching MOTS-c on a database like PubMed will surface the actual published studies. Those listings include limitations, sample sizes, and whether the work was done in animals or people. Reading the original paper, not just an abstract or a forum recap, is the most reliable way to judge where the science actually stands.
What telos rx will and will not say
telos rx did not promise a launch date for MOTS-c while it was unavailable, because none was confirmed. telos rx will also not tell you it works for a specific outcome, because that has not been established in a way that would responsibly support a claim like that.
What telos rx will say is this: the interest in MOTS-c is understandable, the science is genuinely active, and the honest current status is that MOTS-c is offered after provider review, under a temporary HHS policy that is not FDA approval. If that changes, it will be reflected on the product page.
Frequently Asked Questions
Does telos rx sell MOTS-c right now?
Yes. MOTS-c was previously not available, but telos rx now prescribes compounded MOTS-c as a subcutaneous injection after an online intake reviewed by a US-licensed provider. A prescription is required and approval is not guaranteed.
Is MOTS-c FDA-approved?
No peptide discussed here is FDA-approved, and compounded medications generally are not FDA-approved either. telos rx offers compounded MOTS-c after provider review under a temporary HHS policy, which is not FDA approval.
Why did a 2026 committee review matter if nothing changed?
The 2026 Pharmacy Compounding Advisory Committee review produced non-binding recommendations about several research peptides. A recommendation is not an approval, and it did not add MOTS-c to any compounding program on its own. A separate HHS enforcement discretion policy announced on October 28, 2026 now covers compounded single-ingredient MOTS-c under strict conditions, temporarily and without FDA approval.
Is MOTS-c the same as products sold as research chemicals online?
Peptides sold labeled "for research use only" are a distinct category from a compounded prescription. telos rx does not sell or endorse research-labeled products for personal use.
What can I use instead today?
MOTS-c itself is now offered after provider review. telos rx also offers BPC-157, PT-141, NAD+ nasal spray, and sermorelin as compounded protocols with a real intake process.
Where can I check current MOTS-c status?
The MOTS-c page on the telos rx site reflects current program status, including any change if HHS revisits its policy.
telos rx is LegitScript-certified. Compounded medications are not FDA-approved. MOTS-c is offered by telos rx only by prescription, after provider review. This article is general information, not medical advice, and does not replace guidance from your own provider.
Ready to see if MOTS-c fits? Start with the MOTS-c page or learn about NAD+ nasal spray.